Universitätsklinikum Freiburg

Syndromic Inborn Errors of Immunity in TREC-Newborn Screening: 5-year Experience from the German Screening Program (2026) Graafen L, Speckmann C, Bakhtiar S, Bernuth Hv, Lehmberg K, Bader P, Baumann U, et al. Journal article Spatially Restricted Immature Neuronal Programs Drive Functional Connectivity in Glioblastoma (2026) Delev D, Yang D, Grabis E, Ort J, Bak A, Bárány L, Villa G, et al. Unpublished / Preprint Loss-of-function variants in the CAPN1 activator CD99L2 cause X-linked spastic ataxia (2026) Menden B, Incebacak Eltemur RD, Demidov G, Sturm M, Park J, Huridou C, Fath F, et al. Journal article MR Neurography in Children and Adolescents (2026) Preisner F, Garbade SF, Grünert SC, Schwarz D, Jende JM, Kurz FT, Sturm V, et al. Journal article Associations of supramaximal resection with outcome in glioblastoma across age groups: A report of the RANO resect group (2026) Teske N, Dono A, Young JS, Jünger ST, Youssef G, Häni L, Sciortino T, et al. Journal article Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneity (2026) Arrieta VA, Benotmane JK, Du R, Habashy KJ, Zhao J, Najem H, Wang S, et al. Journal article COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma (2026) Weichenthal M, Debus D, Zimmer L, Wasielewski Iv, Meier F, Tüting T, Heppt M, et al. Journal article O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial (2026) Grosu AL, Weber WA, Graf E, Mix M, Nestle U, Schimek-Jasch T, Wiehle R, et al. Journal article Mycophenolate mofetil versus prednisone for the initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children in Germany (INTENT): a multicentre, open-label, randomised, controlled, parallel-group, non-inferiority, phase 3 trial (2026) Benz MR, Sander A, Ehren R, Höcker B, Fichtner A, Gellermann J, Thumfart J, et al. Journal article Real-world progression-free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study (2026) Fasching P, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, et al. Journal article